FHD-286

产品说明书

Print
Chemical Structure| 2671128-05-3 同义名 : -
CAS号 : 2671128-05-3
货号 : A1603632
分子式 : C24H30N6O6S2
纯度 : 99%+
分子量 : 562.662
MDL号 : MFCD34662947
存储条件：

Pure form Sealed in dry,2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 250 mg/mL(444.32 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 FHD-286 is a selective, orally administered inhibitor of the SMARCA4/SMARCA2 ATPase activities of BRG1 and BRM. FHD-286 is being investigated for potential therapeutic applications in BAF (BRG1/BRM-associated factor)-related disorders such as acute myeloid leukemia[1].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.78mL

0.36mL

0.18mL

8.89mL

1.78mL

0.89mL

17.77mL

3.55mL

1.78mL
参考文献

[1]Warren C. Fiskus, et al. Abstract 1140: Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPases BRG1 and BRM by FHD-286 in cellular models of AML. Cancer Res (2023) 83 (7_Supplement): 1140.

[2]Kana Ichikawa, et al. Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models.